Clinical Trial Search

Primary: Number of Participants Who Achieved American College of Rheumatology (ACR) 20 Response at Week 14 — 44; 59; 49; 50 Participants — p=<0.001

Primary: Number of Participants With Any On-treatment Adverse Event (AE) or Any Serious Adverse Event (SAE) — 57; 132; 120; 7 Participants

Primary: Glycosylated Hemoglobin A1C (HbA1c) at Endpoint — 7.50; 7.40 percentage of glycosylated hemoglobin

Primary: Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants — -1.98; -1.45; -1.44…

Primary: Drinks Per Drinking Day — 8.7; 8.9; 9.2 Drinks per drinking day

Primary: Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters — 311; 269; 34; 6 participants

Primary: Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters — 140; 122; 18; 9 participants

Primary: Change From Baseline to the End of Maintenance Period in Total of Each Sum Score of UPDRS Part 2 and Part 3 — -8.4; -4.1 Scores on a scale — p=0.002

Primary: Treatment Response of Xerosis — 71; 48 participants

Primary: Percentages of Overall Subjects With Seroresponse After MenACWY-CRM Vaccination — 85; 74; 60; 83 Percentage of subjects

Primary: Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population — 26; 31; 12; 16 Participants

Primary: Change From Baseline in Mean Percent Predicted Forced Vital Capacity (FVC) at Week 105 — -0.056 percent predicted FVC

Primary: Change in A1C From Baseline to End of Study Participation — 0.00; -0.04 Percent

Primary: Total Passive Extension Deficit (TPED) at Baseline for First Injection — 55.0 degrees

Primary: The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale From 0 to 48 Hours After Trial Entry (VASSPID-48) — 598.670; 623.162…